DUBLIN--(BUSINESS WIRE)--The "Global Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to ResearchAndMarkets.com's offering.
The global hemophilia treatment market was valued at US$ 10,042.7 Million in 2016, and is expected to reach US$ 15,124.7 Million by 2025, expanding at a CAGR of 4.5% from 2017 to 2025.
Rise in funding for research and development, increasing healthcare expenditure, advancement in diagnostic technology would propel the growth of hemophilia treatment market. The World Federation of Hemophilia and WHO both recommend prophylaxis as the optimal therapy for hemophilia. Across North America, Europe and Japan, prophylactic therapies are being widely used. Furthermore, increase in demand on prophylactic treatment and with availability of recombinant factor provides immense growth opportunities of hemophilia market.
The global hemophilia treatment market is segmented by product type into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents and desmopressin. Recombinant coagulation factors are preferred by most physicians, due to low risk of blood borne infection. Thus the segment is anticipated to drive the haemophilia market in the given forecast period.
The global hemophilia treatment market is segmented by hemophilia type into Hemophilia A, Hemophilia B and others. Hemophilia A occupies the largest market share of global hemophilia market due to rising prevalence of hemophilia A and surge in demand of prophylactic treatment.
Key Topics Covered:
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Hemophilia Treatment: Market Dynamics and Future Outlook
Chapter 4. Global Hemophilia Treatment Market, by Product Type, 2015 - 2025 (US$ Mn)
Chapter 5. Global Hemophilia Treatment Market, by Hemophilia Type, 2015 - 2025 (US$ Mn)
Chapter 6. Global Hemophilia Treatment Market, by Geography, 2015 - 2025 (US$ Mn)
Chapter 7. Company Profiles
- Baxter International, Inc.
- Bayer AG
- Biogen Idec, Inc.
- Chugai Pharmaceutical Co.
- CSL Behring
- Genentech, Inc.
- Hospira, Inc.
- Ferring B.V.
- Octapharma AG
- Novo Nordisk
- Pfizer, Inc.
- Sanofi SA
- Swedish Orphan Biovitrum AB
- Shire Plc.
For more information about this report visit https://www.researchandmarkets.com/research/f43d2z/global_hemophilia?w=4